Product Launches

Morepen to Launch Montelukast, An Anti-Asthmatic Drug in North American & European Markets

Company Report

 MUMBAI: Morepen Laboratories a pharmaceutical firm announced that soon it would be selling Montelukast, an anti-asthmatic drug in the North American and European markets. The company expects to generate a global turnover of INR 100 crore for the year 2016-17 from sale of Montelukast.  

In the year 2015-16, the drug contributed a total income of INR 48 crore to the company in the 9-month period. By the end of the fiscal year 2015-16 the total contribution would reach INR 70 crore. By 2016-17, the company expects to generate a global turnover of INR 100 crore from Montelukast drug alone. Owing to the expansion in the production capacities, it is expected that the future sale form Montelukast would reach INR 250-300 crore.  

In India, the Montelukast drug is manufactured at the company’s manufacturing facility at Parwanoo, Himachal Pradesh and is commercially sold to customers in around 32 countries. 

The company has plans to expand the presence of Montelukast drug in untapped international markets. This is expected to increase the exports of this drug in the future. The company's manufacturing plant at Parwanoo would soon start its production by USFDA (US Food and Drug Administrator). Morepen deals into home diagnostics, APIs / bulk drugs, formulations and OTC products. In the 3rd quarter ending December 31, 2015, the company's revenue accounted for INR 7.28 crore with a total income of INR 112 crore, with a growth of 146% and 10% respectively. 

According to the recent report published by Pharmaion, “Global Asthma and COPD Drug Market Opportunities, 2020”, chronic diseases such as, asthma and chronic obstructive pulmonary disease (COPD) are characterized by obstruction or hindrance in the airway of the lungs that lead to respiratory problems. However, breathing problems may also arise from asthma, pneumonia, emphysema, or COPD. Asthma and COPD drugs are used in treating symptoms of Asthma and COPD. According to WHO (World Health Organization), asthma is a very common chronic disease and is mostly found in children. Globally, around 235 million people suffer from asthma. It is found that if asthma is left untreated, it can worsen the patient’s condition by making it difficult for the patient to breathe air in any form. Such patients have swollen airway walls that become narrower when affected. Such patients then have to intake air from an inhaler. 


Relevant Reports

India Pharmacy Market Opportunities, 2011 - 2021

Pharmaceutical | 22 Aug, 2016News

India is the second most populated country globally, with a total population of 1.3 billion as of 2015. More than 50% of the country’s population is in the age group of <25 years. India accounted for ~20% share in the global

Relevant News